Literature DB >> 28604241

Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain.

Daniela Salvemini1, Kenneth A Jacobson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28604241      PMCID： PMC5605777          DOI： 10.1080/13543776.2017.1341018

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN： 1354-3776            Impact factor:   6.674


× No keyword cloud information.
  10 in total

1.  The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model.

Authors:  Katia Varani; Fabrizio Vincenzi; Martina Targa; Beatrice Paradiso; Annapaola Parrilli; Milena Fini; Giovanni Lanza; Pier Andrea Borea
Journal:  Eur J Cancer       Date:  2012-07-05       Impact factor: 9.162

2.  Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Authors:  Zhoumou Chen; Kali Janes; Collin Chen; Tim Doyle; Leesa Bryant; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

Review 3.  New perspectives for chronic pain treatment: a patent review (2010-2016).

Authors:  Lícia T S Pina; Daniele N Gouveia; Janara S Costa; Jullyana S S Quintans; Lucindo J Quintans-Júnior; Rosana S S Barreto; Adriana G Guimarães
Journal:  Expert Opin Ther Pat       Date:  2017-03-03       Impact factor: 6.674

Review 4.  Recent trends in neuropathic pain patents.

Authors:  Rodolfo do Couto Maia
Journal:  Expert Opin Ther Pat       Date:  2016-12-28       Impact factor: 6.674

5.  Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.

Authors:  Joshua W Little; Amanda Ford; Ashley M Symons-Liguori; Zhoumou Chen; Kali Janes; Timothy Doyle; Jennifer Xie; Livio Luongo; Dillip K Tosh; Sabatino Maione; Kirsty Bannister; Anthony H Dickenson; Todd W Vanderah; Frank Porreca; Kenneth A Jacobson; Daniela Salvemini
Journal:  Brain       Date:  2014-11-19       Impact factor: 13.501

6.  Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.

Authors:  Dilip K Tosh; Steven Crane; Zhoumou Chen; Silvia Paoletta; Zhan-Guo Gao; Elizabeth Gizewski; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2015-05-20       Impact factor: 4.345

Review 7.  Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Authors:  K Janes; A M Symons-Liguori; K A Jacobson; D Salvemini
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

8.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man.

Authors:  G J Bennett; Y K Xie
Journal:  Pain       Date:  1988-04       Impact factor: 6.961

9.  Role of A3 adenosine receptor in diabetic neuropathy.

Authors:  Heng Yan; Enshui Zhang; Chang Feng; Xin Zhao
Journal:  J Neurosci Res       Date:  2016-06-19       Impact factor: 4.164

10.  5'-Chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A(1) receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions.

Authors:  Livio Luongo; Riccardo Petrelli; Luisa Gatta; Catia Giordano; Francesca Guida; Patrizia Vita; Palmarisa Franchetti; Mario Grifantini; Vito de Novellis; Loredana Cappellacci; Sabatino Maione
Journal:  Molecules       Date:  2012-11-22       Impact factor: 4.411
  10 in total
  7 in total

1.  A binding kinetics study of human adenosine A3 receptor agonists.

Authors:  Lizi Xia; Athina Kyrizaki; Dilip K Tosh; Tirsa T van Duijl; Jacomina Cornelia Roorda; Kenneth A Jacobson; Adriaan P IJzerman; Laura H Heitman
Journal:  Biochem Pharmacol       Date:  2018-01-03       Impact factor: 5.858

2.  Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation.

Authors:  Courtney L Fisher; Lucas B Fallot; Tina C Wan; Robert F Keyes; R Rama Suresh; Amy C Rothwell; Zhan-Guo Gao; John D McCorvy; Brian C Smith; Kenneth A Jacobson; John A Auchampach
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-15

3.  Adenosine A3 receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury.

Authors:  Susan A Farr; Salvatore Cuzzocrea; Emanuela Esposito; Michela Campolo; Michael L Niehoff; Timothy M Doyle; Daniela Salvemini
Journal:  J Neuroinflammation       Date:  2020-11-12       Impact factor: 8.322

4.  Spinal A3 adenosine receptor activation acutely restores morphine antinociception in opioid tolerant male rats.

Authors:  Heather Leduc-Pessah; Cynthia Xu; Churmy Y Fan; Rebecca Dalgarno; Yuta Kohro; Sydney Sparanese; Nikita N Burke; Kenneth A Jacobson; Christophe Altier; Daniela Salvemini; Tuan Trang
Journal:  J Neurosci Res       Date:  2021-06-01       Impact factor: 4.433

5.  Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels.

Authors:  Elena Lucarini; Elisabetta Coppi; Laura Micheli; Carmen Parisio; Alessia Vona; Federica Cherchi; Anna M Pugliese; Felicita Pedata; Paola Failli; Seph Palomino; Jared Wahl; Tally M Largent-Milnes; Todd W Vanderah; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

Review 6.  Neonatal Seizures and Purinergic Signalling.

Authors:  Aida Menéndez Méndez; Jonathon Smith; Tobias Engel
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

Review 7.  Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?

Authors:  Stefania Merighi; Tino Emanuele Poloni; Anna Terrazzan; Eva Moretti; Stefania Gessi; Davide Ferrari
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.